ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: 16 hours ago

283.54

-2.47 (-0.86%)

Previous Close 286.01
Volume 5,014,775
Price / Earnings (Forward) 18.06
Price / Sales 7.86
52 Weeks Range
190.75 (-32%) — 302.93 (6%)
TTM Dividend Yield 3.18%
Profit Margin 7.31%
Operating Margin (TTM) 30.43%
Diluted EPS (TTM) 2.35
Quarterly Revenue Growth (YOY) 8.40%
Quarterly Earnings Growth (YOY) -6.10%
Total Debt/Equity (MRQ) 4,789.60%
Current Ratio (MRQ) 0.760
Operating Cash Flow (TTM) 16.40 B
Levered Free Cash Flow (TTM) 16.94 B
Return on Assets (TTM) 8.34%
Return on Equity (TTM) 88.40%

AIStockmoo Score

0.3
Neutral for 2 days
Dearer than its usual valuation. info
Earns about its cost of capital. Returns on capital falling. info
High debt. Strong profitability. Thin short-term liquidity. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Trading near its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
Insiders net selling recently. info
Institutions net +1.39% of shares in their latest 13F filings: 2,143 holders increased, 1,888 decreased (quarter to 30 Sep 2026). info
Market environment cautious. info
Sector outperforming the market.
The pillars disagree, so the score is softened.
Earnings per share have mostly fallen. Earnings have been uneven. info
Above its medium-term trend line. info
Price is high against its 52-week average. Up over 5 years. info
Short-term momentum fading. info
Price is near support. info
Final Score 0.27
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bullish
Drug Manufacturers - General (Global) Mixed Bullish
Stock AbbVie Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
ABBV - 3.18% - - 0.3
NVO 171 B 29.67% 9.82 5.27 0.0
PFE 157 B 7.66% 39.34 1.80 0.7
BMY 119 B 4.23% 12.94 5.20 1.4
GSK 96 B 1.42% 16.43 3.92 -0.1
JNJ - 1.92% - 8.05 1.1

Select this tab to load the latest available analysis.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 74.87%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
STEWART JEFFREY RYAN - 293.39 -44,069 -12,929,405
Aggregate Net Quantity -44,069
Aggregate Net Value ($) -12,929,405
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 293.39
Name Holder Date Type Quantity Price Value ($)
STEWART JEFFREY RYAN Officer 12 Nov 2026 Disposed (-) 3,450 294.45 1,015,853
STEWART JEFFREY RYAN Officer 09 Nov 2026 Sell (-) 40,619 293.30 11,913,553
STEWART JEFFREY RYAN Officer 09 Nov 2026 Option execute 40,619 - -

Institutions

Institutional ownership: 86.87%

Positions Holders Shares
Increased 2,143 61,697,401
Decreased 1,888 42,902,084
New 224 8,979,063
Sold out 107 3,122,065

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

14 Positive 0 Negative 8 Neutral
Date Type Details
19 Nov 2026 Yahoo Finance Does AbbVie (ABBV) Need This New Solid Tumor Cancer Partnership?
AbbVie (NYSE:ABBV) and DISCO Pharmaceuticals announced a new collaboration to develop bispecific cancer therapies for solid tumors. The agreement focuses on applying DISCO Pharmaceuticals' proprietary bispecific technology platform to AbbVie's oncology research programs. The partnership is intended…
19 Nov 2026 Yahoo Finance AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics
The drugs developed through this collaboration will look to address significant unmet needs plaguing the solid tumour space.
19 Nov 2026 Yahoo Finance DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research and development expertise to identify and potentially advance highly selective AND-gated bispecific therapeutics. Upon…
17 Nov 2026 Yahoo Finance How Did AbbVie's Neuroscience Franchise Perform in Q3?
ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.
17 Nov 2026 Yahoo Finance Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
17 Nov 2026 Yahoo Finance AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
Key TakeawaysBarclays raised its AbbVie price target to $335 from $325 on Nov. 16 and kept its Overweight rating, after a run that has the stock up 27% in a year.
16 Nov 2026 Yahoo Finance AbbVie (ABBV) Expands Its Pipeline With New AI Drug Discovery Partnerships
AbbVie (NYSE:ABBV) has entered a new AI-driven drug discovery collaboration with Iambic to support its research pipeline. The pharmaceutical group is advancing its partnership with Brise Pharmaceuticals, gaining global development and commercialization rights for preclinical migraine programs.…
16 Nov 2026 Yahoo Finance Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and partnership activitiesSigned AI discovery collaborations with Bayer and AbbVie; eight total partnerships signed since 2024Achieved a program milestone in…
16 Nov 2026 Yahoo Finance ETFs Are Net Sellers of AbbVie (ABBV) on Nov. 12
ETFs sold a net $62.0 million of AbbVie on Thursday, with 40 funds buying and 16 selling.
14 Nov 2026 Yahoo Finance Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
These healthcare dividend stocks appeal to investors in different ways.
13 Nov 2026 Yahoo Finance AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth
AbbVie has delivered a strong share price run in recent years, and with the stock around US$295 the key question is how firmly its current market value rests on the cash it can generate over time. The stock has returned 203.1% over 5 years, which places substantial expectations into the price and…
13 Nov 2026 Yahoo Finance AbbVie or Johnson & Johnson: Only One Gets My Dividend Dollars for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5% on Oct. 30, while Johnson & Johnson took a $5…
12 Nov 2026 Yahoo Finance 3 Pharmaceutical Stocks That Offer Safety and Growth
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.
12 Nov 2026 Yahoo Finance How Did AbbVie's Immunology Franchise Fare in Q3?
ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.
12 Nov 2026 Yahoo Finance AbbVie Deal Altering The Investment Case For Nxera Pharma Stock (TSE:4565)?
Nxera Pharma announced in early November 2026 that its UK subsidiary entered an exclusive global license agreement with AbbVie for the EP4 agonist program in inflammatory bowel disease. The agreement includes a US$100 million upfront payment and potential milestones up to US$1.37 billion, plus…
12 Nov 2026 Yahoo Finance The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira
NVDA, WMT and ABBV headline Zacks' latest research, with growth drivers and business risks shaping their investment outlooks.
12 Nov 2026 Yahoo Finance Coca-Cola or AbbVie: The One Dividend Stock I’d Hold for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5. 2% to $1…
12 Nov 2026 Yahoo Finance AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
AbbVie (NYSE:ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention against topiramate. The TEMPLE study found QULIPTA achieved superior tolerability compared with topiramate in adults with migraine. QULIPTA also showed better efficacy than topiramate on key…
11 Nov 2026 Yahoo Finance Top Analyst Reports for NVIDIA, Walmart & AbbVie
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL).
11 Nov 2026 Yahoo Finance ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
11 Nov 2026 Yahoo Finance 3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent.
10 Nov 2026 Yahoo Finance Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
AbbVie (ABBV) just raised its full year 2026 revenue guidance to about US$67.8b and lifted its dividend, after reporting third quarter sales of US$17.4b and net income of US$4.2b. Recent price action has been strong, with AbbVie’s share price delivering a 6.1% 1 month gain and a 17.3% 3 month share…
Show more
TTM Dividend Yield 3.18%
5Y Average Dividend Yield 3.22%
Payout Ratio 268.80%
Ex Date Announcement Date Payment Date Details
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Cash
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Cash
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Cash
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Cash
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them.
Nearest support: 276.33 – 282.91 · strong level
Nearest resistance: 287.91 – 293.08 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria